Pacira BioSciences Inc (NAS:PCRX)
$ 17.24 -0.46 (-2.6%) Market Cap: 796.03 Mil Enterprise Value: 986.64 Mil PE Ratio: 0 PB Ratio: 1.06 GF Score: 71/100

Pacira Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 02:15PM GMT
Release Date Price: $71.37 (+1.10%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Good morning, everyone. My name is Balaji Prasad. I lead the Specialty Pharmaceuticals coverage for Barclays. Continuing on day 2 of our spec pharma track, I'm delighted to have the management team of Pacira with us. So from Pacira, we have Dave Stack, Chairman and CEO; and Charles Reinhart, CFO.

Dave and Charlie, thank you for taking your time and joining us today.

David M. Stack
Pacira BioSciences, Inc. - Chairman & CEO

Thank you for the opportunity.

Questions & Answers

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Fantastic. So I think as we look now with the updates that you had recently, and you also provided the Feb monthly sales. The question that I have been getting in the past few weeks since the Q4 call is really about ZILRETTA. I think there still seems to be significant confusion over the manufacturing issues on the contract rates that you had and what it means for your 2020 outlook with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot